JP2024539139A5 - - Google Patents

Info

Publication number
JP2024539139A5
JP2024539139A5 JP2024523624A JP2024523624A JP2024539139A5 JP 2024539139 A5 JP2024539139 A5 JP 2024539139A5 JP 2024523624 A JP2024523624 A JP 2024523624A JP 2024523624 A JP2024523624 A JP 2024523624A JP 2024539139 A5 JP2024539139 A5 JP 2024539139A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
heterodimer
hil12fc
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539139A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/078465 external-priority patent/WO2023070056A2/en
Publication of JP2024539139A publication Critical patent/JP2024539139A/ja
Publication of JP2024539139A5 publication Critical patent/JP2024539139A5/ja
Pending legal-status Critical Current

Links

JP2024523624A 2021-10-20 2022-10-20 ヘテロ二量体fcサイトカインおよびその使用 Pending JP2024539139A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163257913P 2021-10-20 2021-10-20
US63/257,913 2021-10-20
PCT/US2022/078465 WO2023070056A2 (en) 2021-10-20 2022-10-20 Heterodimeric fc cytokines and uses thereof

Publications (2)

Publication Number Publication Date
JP2024539139A JP2024539139A (ja) 2024-10-28
JP2024539139A5 true JP2024539139A5 (cg-RX-API-DMAC10.html) 2025-10-22

Family

ID=86059699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523624A Pending JP2024539139A (ja) 2021-10-20 2022-10-20 ヘテロ二量体fcサイトカインおよびその使用

Country Status (11)

Country Link
US (2) US12522639B2 (cg-RX-API-DMAC10.html)
EP (1) EP4419545A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024539139A (cg-RX-API-DMAC10.html)
KR (1) KR20240099287A (cg-RX-API-DMAC10.html)
CN (1) CN118451096A (cg-RX-API-DMAC10.html)
AU (1) AU2022369312A1 (cg-RX-API-DMAC10.html)
CA (1) CA3234552A1 (cg-RX-API-DMAC10.html)
IL (1) IL312221A (cg-RX-API-DMAC10.html)
MX (1) MX2024004763A (cg-RX-API-DMAC10.html)
WO (1) WO2023070056A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA202403036B (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230010251A (ko) 2020-05-13 2023-01-18 보넘 테라퓨틱스, 인크. 단백질 복합체의 조성물 및 그의 사용 방법
IL312221A (en) * 2021-10-20 2024-06-01 Synthekine Inc Heterodimeric fc cytokines and uses thereof
US20240150422A1 (en) * 2022-07-18 2024-05-09 Onko-Innate Pty Ltd Il-12 fc fusion proteins and uses thereof
WO2024238212A1 (en) * 2023-05-12 2024-11-21 Chimeris Uk Ltd. Car t-cells secreting specificity detuned cytokine il-12
EP4739701A2 (en) * 2023-07-07 2026-05-13 Technische Universität München, in Vertretung des Freistaats Bayern Muteins of human interleukin 12
AU2024407051A1 (en) 2023-12-18 2026-07-30 Genzyme Corporation Il-12 loss of potency muteins
CN120077060A (zh) * 2024-08-16 2025-05-30 程联胜 白介素12突变体及其用途
WO2026123351A1 (en) * 2024-12-13 2026-06-18 Zai Lab (Shanghai) Co., Ltd. Interleukin-12 p40 variants, pd-1 antigen-binding domains and uses thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5573764A (en) 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
ES2464532T3 (es) 2001-04-19 2014-06-03 The Scripps Research Institute Métodos y composiciones para la producción de pares ortogonales de ARNt-aminoacil-ARNt sintetasa
ATE440864T1 (de) 2003-03-10 2009-09-15 Schering Corp Verwendung von il-23-antagonisten; verwandte reagenzien
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US8802643B1 (en) 2003-05-30 2014-08-12 University Of South Florida Method for the treatment of malignancies
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CN103145837A (zh) 2005-06-30 2013-06-12 Abbvie公司 Il-12/p40结合蛋白
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
SI1966238T1 (sl) 2005-12-30 2012-08-31 Merck Patent Gmbh Variante interlevkina-12P40 z izboljšano stabilnostjo
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Fcポリペプチドおよび使用方法
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
WO2014054804A1 (ja) 2012-10-05 2014-04-10 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
EP3421495A3 (en) 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
WO2015124297A1 (en) 2014-02-19 2015-08-27 Merck Patent Gmbh Cancer-targeted il-12 immunotherapy
SG11201702295UA (en) 2014-09-22 2017-04-27 Intrexon Corp Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
US11087249B2 (en) 2016-05-24 2021-08-10 Ciambella Ltd. Method and apparatus for triggering execution of a workflow over a network
EP3511340B1 (en) 2016-08-10 2024-10-02 Ajou University Industry-Academic Cooperation Foundation Heterodimeric fc-fused cytokine and pharmaceutical composition comprising the same
US10232053B2 (en) 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
SE541511C2 (sv) 2017-03-06 2019-10-22 Slaettberg Fredrik Installationsklara vägg- och regelkassetter
CN110101843A (zh) 2018-02-01 2019-08-09 北京科诺科服生物科技有限公司 一种抗肿瘤蛋白质及其应用
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CN110396133B (zh) 2018-04-25 2021-07-23 免疫靶向有限公司 一种以白介素12为活性成分的融合蛋白型药物前体
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
KR102884523B1 (ko) 2018-10-03 2025-11-10 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
KR20210080460A (ko) * 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
AU2020316002B2 (en) 2019-07-25 2026-05-07 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
EP4037700A2 (en) 2019-10-03 2022-08-10 Xencor, Inc. Targeted il-12 heterodimeric fc-fusion proteins
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物
MX2022008770A (es) 2020-01-14 2022-10-07 Synthekine Inc Muteinas de la il2.
JP7851612B2 (ja) 2020-04-17 2026-04-27 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 改変il-12及びil-23ポリペプチドとその使用
AU2021260960A1 (en) 2020-04-22 2022-11-24 Dragonfly Therapeutics, Inc. Formulation, dosage regimen, and manufacturing process for heterodimeric Fc-fused proteins
US12454695B2 (en) 2021-05-05 2025-10-28 Ankyra Therapeutics, Inc. Fusion polypeptides comprising interleukin 12 and a metal-hydroxide binding polypeptide
WO2023070038A2 (en) * 2021-10-20 2023-04-27 Synthekine, Inc. Human il-12p40 variants and uses thereof
IL312221A (en) * 2021-10-20 2024-06-01 Synthekine Inc Heterodimeric fc cytokines and uses thereof

Similar Documents

Publication Publication Date Title
JP2024016093A (ja) IgM血清半減期に影響を及ぼすIgM Fc及びJ鎖の変異
KR101224335B1 (ko) 글루카곤-유사 단백질-1 수용기(glp-1r) 작용제 화합물
JP2021533779A5 (cg-RX-API-DMAC10.html)
WO2005040217B1 (en) Antibodies having a mutated amino acid residue at position 268 (ch2 region) in constant regions
JP2023518434A5 (cg-RX-API-DMAC10.html)
CN115698052A (zh) 白介素2突变体及其用途
WO1993011162A1 (en) Bispecific antibody heterodimers
JP2023554119A5 (cg-RX-API-DMAC10.html)
JP7752664B2 (ja) 新規な中間体製造による持続型薬物結合体の製造方法
JP2023530335A5 (cg-RX-API-DMAC10.html)
JP2024504923A5 (cg-RX-API-DMAC10.html)
JP2025540100A (ja) 突然変異体il-2ポリペプチドおよびil-2プロドラッグ
EP4559932A1 (en) Multispecific antibody and use thereof
US20250339519A1 (en) Combination of cytokine fusion proteins with cd8 antigen binding molecules
EP4232062A1 (en) Bifunctional antagonists of activin and tumor necrosis factor-alpha and uses thereof
WO2023158027A1 (en) A fusion protein comprising an antigen binding domain and a cytokine trimer domain
JP2005529583A (ja) ポリペプチド変異体
JP2023503789A (ja) 抗cd25抗体-マイタンシンコンジュゲートおよびその使用方法
WO2024144336A1 (ko) 신규 이중 특이성 융합단백질 및 그의 용도
KR20230112629A (ko) 종양괴사인자-알파 및 형질전환성장인자-베타의 이작용성 길항제 및 이의 용도
CN116635059A (zh) 激活蛋白和肿瘤坏死因子-α的双功能拮抗剂及其用途
CN118510802A (zh) Cd20-pd1结合分子及其使用方法
JP2021510162A5 (cg-RX-API-DMAC10.html)
KR20230118573A (ko) 액티빈/tgf-베타 및 rankl의 이작용성 길항제 및 이의 용도